Loading...
First-Line Treatment with a Cyclin-Dependent Kinase 4/6 Inhibitor Plus an Aromatase Inhibitor for Metastatic Breast Cancer in Alberta
In this analysis, we describe population-based outcomes for first-line treatment with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) combined with an aromatase inhibitor (AI). All patients who were prescribed CDK4/6i + AI from January 2016 through June 2019 were included. Patient demographics, tu...
Saved in:
| Published in: | Curr Oncol |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
MDPI
2021
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8293123/ https://ncbi.nlm.nih.gov/pubmed/34207443 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/curroncol28030209 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|